Compare Crispr Therapeutics AG (CRSP) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Tesla, Inc. — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while Tesla, Inc. trades at $396.55 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 299.8× Crispr Therapeutics AG's market cap, and Tesla, Inc. is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | TSLA | |
|---|---|---|
Market Cap | $4.97B | $1.49T |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $489.88 |
52-Week Low | $44.34 | $302.63 |
Enterprise Value | $3.32B | $1.46T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Tesla (TSLA) trades at $394.76, down 3.18% today amid a bearish technical signal. The stock faces pressure from elevated valuations with a P/E of 362.17 and P/S of 14.25, while recent earnings show mixed results with a Q1 2026 beat but a Q3 2025 miss. Cash flow remains positive at $579M in 2025, though net income margins have compressed to 3.95% from prior years. News highlights focus on autonomous driving approvals in Europe and a potential cheaper EV model.
The outlook is cautious; while analyst consensus is a Buy with a $409.26 target, risks include intense EV competition, execution on AI/robotics bets, and high valuation multiples. Near-term performance hinges on Q2 2026 earnings and delivery growth, with support at $391 and resistance at $399.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
